Rosiglitazone and the case for safety over certainty

JAMA

Volumn 304, Issue 4, 2010, Pages 469-471

  Juurlink, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PIOGLITAZONE; ROSIGLITAZONE; VITAMIN D;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; STROKE;

EID: 77954972256     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.954     Document Type: Editorial

References (19)

1. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373(9681):2088-2090.
2. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78(9):1088-1091. (Pubitemid 37055653)
3. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A. 2005;102 (26):9406-9411.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
5. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH; American Heart Association; American College Of Cardiology Foundation. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2010; 55(17):1885-1894.
6. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
7. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone [published online ahead of print June 28, 2010]. JAMA. 2010;304(4):411-418. doi:10.1001/JAMA.2010.920.
8. Goldberg RB, Kendall DM, Deeg MA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-1554.
9. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284(2):751-759.
10. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942.
11. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008;168(21):2368-2375.
12. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One. 2009;4(6):e6080.
13. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
14. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
15. Macklin R. Letter to FDA Commissioner Margaret Hamburg, MD. http://www .citizen.org/. May 25, 2010. Accessed June 22, 2010.
16. Juurlink DN, Wolfe S. Letter urging FDA to halt rosiglitazone (Avandia) trial. http://www.citizen.org/. May 11, 2010. Accessed June 22, 2010.
17. Mundy A. Glaxo's Avandia study lags in recruiting. Wall Street Journal Web site. http://online.wsj.com/. May 10, 2010. Accessed June 22, 2010.
18. GSK Clinical Trials. Thiazolidinedione Intervention with vitamin D Evaluation (TIDE). clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/ show /NCT00879970. Accessed June 22, 2010.
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.